EU Clinical Trial 2019-001199-12

Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Patients With Moderately or Severely Active Crohn's Disease  May 28, 2019

Main objective of the trial: To evaluate efficacy of MLN0002 in induction and maintenance therapy in Japanese subjects with moderately or severely active Crohn's disease.

Parties

Sponsors
Countries
EU JP
Keywords
Entyvio MLN0002 vedolizumab

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.